About the Company
enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ENOB News
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
(Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a ...
Enochian BioSciences Inc (2Q5.BE)
*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
HRMY Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the ...
PCRX Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in ...
EVOFEM BIOSCIENCE INC by Evofem Biosciences, Inc. Stock (OTC:EVFM), Short Interest Report
Looking for the most shorted stocks?
Forte Biosciences Inc.
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...
Pulse Biosciences, Inc. (PLSE)
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript March 28, 2024 Pulse Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
Cellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?
We feel now is a pretty good time to analyse Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) business as it appears the company may be on the cusp of a considerable accomplishment. Cellectar ...
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript
Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript March 28, 2024 Pulse Biosciences, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase ...
Pacira BioSciences Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Call Transcript
Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Call Transcript March 28, 2024 Arcadia Biosciences, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...
Loading the latest forecasts...